4DMedical (ASX: 4DX) jumps 13% as SimonMed rollout nears

4DMedical Limited (ASX: 4DX) shares jumped 13.08% to A$3.63 on July 31 after the respiratory imaging technology company reported record scan volumes, 23% annual operating revenue growth and a major step towards commercial deployment through SimonMed Imaging in the United States. The company delivered 105,970 scans during the June quarter and ended fiscal 2026 with A$278 million in cash. However, its approximately A$2.18 billion market capitalisation remains strikingly large beside annual operating revenue of A$7.2 million. The next test is whether SimonMed’s network of more than 170 imaging centres can convert rising clinical use into substantially stronger paid revenue.

What does 4DMedical currently sell and how is its lung imaging technology differentiated?

4DMedical develops software that converts standard chest X-ray and computed tomography images into quantitative information about how different regions of a patient’s lungs function. Its products are designed to give clinicians more detailed information than conventional structural imaging or broad pulmonary function tests can provide on their own.

The company’s principal commercial platform is built around XV Technology, which analyses lung motion and airflow. CT:VQ uses non-contrast computed tomography scans to provide regional ventilation and perfusion information, potentially avoiding the need for contrast agents or nuclear medicine procedures in selected clinical settings.

The commercial model is primarily software-based. Hospitals, radiology groups and other healthcare providers can access the technology through subscriptions or per-scan arrangements, allowing 4DMedical to generate revenue without supplying entirely new imaging hardware for every site. The software can be integrated into existing imaging workflows, which may make adoption easier than products requiring hospitals to replace expensive equipment.

That distinction matters because the clinical value of the technology is only one part of the commercial equation. Healthcare providers also need compatible workflows, reimbursement, trained staff and evidence that the software improves diagnostic or treatment decisions. The scalability argument becomes stronger when customers move beyond evaluations and begin processing growing volumes of paid scans.

Why did record scan volumes and the SimonMed agreement attract renewed investor attention?

4DMedical reported fiscal 2026 operating revenue of A$7.2 million, up 23% from the previous corresponding period. Gross margins remained above 90%, reflecting the attractive economics that can be generated when software revenue grows faster than the underlying cost of processing additional scans.

The installed base reached 540 sites globally at June 30, an increase of 39% over one year and 63 sites during the June quarter. This figure does not include SimonMed Imaging. Total scan analysis volume increased 77% to 344,075 scans for the financial year, while the June quarter produced a record 105,970 scans, up 43% from the corresponding period and 23% from the March quarter.

SimonMed is the most important immediate commercial development. The physician-led radiology company operates more than 170 imaging centres across 10 US states and employs more than 300 radiologists. Under a three-year agreement, SimonMed will deploy CT:VQ and Lung Density Analysis functional imaging alongside its existing computed tomography services.

The arrangement uses 4DMedical’s per-scan pricing and does not include an evaluation period. Onboarding has been completed, with clinical deployment on commercial terms described as imminent. That creates a clearer revenue opportunity than a trial or memorandum of understanding because payment is connected to actual utilisation.

The unresolved variable is scan volume. A network of 170 centres provides substantial distribution potential, but it does not reveal how many sites will activate the software immediately, how many physicians will adopt it or how quickly eligible patients will be identified. The value of the agreement will emerge through paid scans and revenue rather than the headline size of SimonMed’s network.

What are the next measurable milestones for the CT:VQ commercial rollout?

The first proof point will be evidence that SimonMed has begun processing paid CT:VQ scans at scale. Investors will be looking for the number of activated imaging centres, scan growth, revenue per scan and indications that clinicians are incorporating the reports into routine patient care.

Fiscal 2026 full-year results are expected during August, based on 4DMedical’s established reporting timetable, although a firm release date had not been announced as of August 2. The audited accounts should provide a more complete view of operating expenses, acquisition spending, statutory losses, customer receipts and the effect of the company’s expanded capital base.

The next quarterly report will be even more important for commercial interpretation. The July update confirms that scan activity is increasing, but SimonMed had not yet contributed to the reported 540-site total or fiscal 2026 revenue. A material increase in paid scan receipts during fiscal 2027 would provide stronger evidence that the company is progressing from clinical adoption towards commercial scale.

The AIRCARE for Vets Act represents a separate potential catalyst. The bipartisan proposal would direct the United States Department of Veterans Affairs to establish a pilot programme using qualifying four-dimensional functional lung imaging and would authorise US$20 million in funding.

The bill has been introduced and referred to the House Committee on Veterans’ Affairs, but it has not been enacted. It should therefore be treated as a possible pathway rather than contracted revenue. Even if the legislation progresses, 4DMedical would still need to secure participation under the programme and convert that opportunity into a commercial agreement.

Can expansion across Australia and Europe turn 4DMedical into a broader lung health platform?

CT:VQ has received approval from Australia’s Therapeutic Goods Administration, and 4DMedical said multiple paid Australian contracts had been executed with patient scanning already underway. This expands the product beyond its United States base and gives the company another market in which to test reimbursement, workflow integration and clinician adoption.

The European strategy has accelerated through the completed acquisition of Vienna-based contextflow. The business brings a European commercial and regulatory presence, a CE-marked lung cancer screening product, established clinical relationships and reimbursement arrangements in Germany.

The original acquisition terms included approximately A$18.56 million in upfront cash, 56,235 ordinary shares and up to 2.59 million zero-exercise-price options linked to performance milestones. The acquisition gives 4DMedical a faster route into Europe than building an entirely new regional organisation, but the investment case now depends on successful integration and cross-selling.

4DMedical has also invested in RevealDx and partnered with Azra AI. These additions are intended to broaden the platform into malignancy risk assessment, patient identification, navigation and follow-up care. Separately, a one-year engagement with GlaxoSmithKline covers quantitative lung imaging analytics for pulmonary drug development.

The broader portfolio may increase the value of each healthcare relationship by connecting screening, diagnosis, functional imaging and patient management. It also increases execution demands. Management must integrate acquired products, regulatory frameworks and commercial teams without allowing operating costs to run materially ahead of revenue.

Does A$278 million of cash remove funding risk from the 4DX investment case?

4DMedical held A$277.95 million in cash at June 30. Net cash used in operating activities was approximately A$9.26 million during the June quarter, giving the company an estimated 30 quarters of funding at that quarterly expenditure rate.

This is a substantially stronger position than many commercial-stage medical technology companies. It gives 4DMedical the capacity to fund sales expansion, clinical evidence programmes, product development and acquisition integration without requiring an immediate equity raise.

The runway calculation should not be treated as a forecast. Spending may increase as SimonMed deployment accelerates, European operations are integrated and additional clinical studies begin. The contextflow acquisition also requires cash and may involve further contingent consideration if performance milestones are achieved.

The company additionally has a secured A$10 million facility from Pro Medicus Limited, carrying a 12.5% rate over its maturity period and due in August 2027. Its repayment structure includes a cash component and an equity-linked component affected by 4DMedical’s share price.

That structure created a A$137.8 million non-cash remeasurement expense during the first half, contributing to a statutory net loss of A$153.9 million. The company reported an adjusted net loss of A$16.2 million after excluding specified non-cash and non-recurring items.

The half-year auditor’s review also contained a qualified opinion concerning the carrying value of goodwill and other intangible assets. This does not negate the company’s large cash balance or commercial progress, but it means investors need to distinguish operating performance from accounting effects and monitor how acquired assets are valued in the full-year accounts.

How is the market pricing 4DMedical after the July 31 share-price rally?

4DMedical closed at A$3.63 on July 31 after trading between A$3.22 and A$3.65. Approximately 7.33 million shares changed hands, compared with a previous close of A$3.21.

The stock gained about 16.7% over the five sessions measured from its July 24 close of A$3.11. However, the shares remained approximately 19.9% below the A$4.53 close recorded on June 30, showing that the latest rally recovered only part of the preceding monthly decline.

The 52-week range extends from A$0.23 to A$7.55. The July 31 close was approximately 52% below the peak but more than 14 times the low. This unusually wide range reflects how rapidly the market has changed its expectations for 4DMedical’s commercial potential.

At A$3.63, the company carried a displayed market capitalisation of approximately A$2.18 billion. That is more than 300 times fiscal 2026 operating revenue of A$7.2 million, although the comparison does not adjust for the company’s A$278 million cash balance.

A conventional earnings multiple is not useful because 4DMedical remains loss-making. The valuation instead reflects expectations that current contracts, clinical evidence, regulatory approvals and international expansion will produce a steep increase in revenue.

The market is therefore not valuing 4DMedical as a A$7.2 million revenue business. It is valuing the probability that the installed base and cash resources can support a much larger global medical imaging platform. Even substantial revenue growth may not automatically lead to a higher valuation if the rate of growth falls below those embedded expectations.

What evidence would strengthen or weaken the 4DMedical investment case from here?

The strongest evidence would be a visible increase in paid CT:VQ scans through SimonMed, supported by customer receipts and recurring or repeat usage. Commercial deployment across a meaningful portion of SimonMed’s network would demonstrate that the agreement is more than a distribution opportunity.

Revenue growth must also begin catching up with operational growth. Scan volumes increased 77% in fiscal 2026, while operating revenue rose 23%. The two measures will not always move together because of product mix, subscriptions, trials and contract structures, but the gap highlights why investors need greater visibility into revenue generated per site and per scan.

The investment case would also strengthen through successful contextflow integration, expanding European contracts and evidence that Australian approval is generating recurring clinical use. Progress of the AIRCARE for Vets Act could increase the United States government opportunity, although the legislation remains conditional and should not be incorporated as assured revenue.

The principal downside scenario is that sites and scans continue increasing without a comparable improvement in commercial revenue. A second risk is that expansion spending and acquisition integration keep operating losses elevated even with the company’s large cash reserve.

A third risk is valuation compression. At approximately A$2.18 billion, the company must deliver more than incremental adoption to justify the current market value. The July quarterly report improved the operating picture, but the decisive evidence will come from paid deployment, revenue conversion and a credible path towards cash-generating scale.

Key takeaways for investors watching 4DMedical Limited after its July rally

• 4DMedical Limited (ASX: 4DX) closed 13.08% higher at A$3.63 after reporting record quarterly scan volumes and 23% fiscal 2026 operating revenue growth.
• The company processed 105,970 scans during the June quarter and 344,075 during fiscal 2026, while its installed base reached 540 sites excluding SimonMed.
• SimonMed’s network of more than 170 US imaging centres is the most important near-term commercial opportunity, with onboarding completed and paid deployment expected to begin.
• Fiscal 2026 operating revenue reached A$7.2 million with gross margins above 90%, while cash stood at approximately A$278 million.
• The large cash reserve reduces near-term funding pressure, although commercial expansion, acquisitions and clinical programmes may increase future expenditure.
• 4DMedical’s approximately A$2.18 billion market capitalisation already assumes a major increase in revenue, making paid scan conversion more important than site-count growth alone.
• The next evidence investors need is SimonMed utilisation, stronger customer receipts, successful European integration and detailed fiscal 2026 financial results.